Knowledge Center

Explore our library of blogs, short videos, virtual event recordings and training topics

Pages for “pharmaceutical”

Recent Blogs

FDA Releases MoCRA Draft Guidance
FDA Releases MoCRA Draft Guidance

On August 7, 2023, the Food and Drug Administration (FDA) released draft guidance providing recommendations and instructions pertaining to the collection and submission of information related to the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), specifically, to assist persons submitting cosmetic product facility registrations and product listings to FDA. 

read more
FDA has Updated eCTD Guidance to Recommend Structure-Data Files
FDA has Updated eCTD Guidance to Recommend Structure-Data Files

Effective March 10, 2023, Health Canada changed submission requirements for second-language product monographs for human drugs. This change no longer requires the second language product monograph at the time of submission filing or review. However, both English and French languages need to be on the Drug Product Database (DPD) online and Drug and Health Product Portal (DHPP).

read more
Simplifying Annual Drug Sample Reporting
Simplifying Annual Drug Sample Reporting

Pharma manufacturers and authorized distributors need to submit distribution reports electronically in an eXtensible Markup Language (XML) format to comply with the guidance entitled Reporting Drug Sample Information Under Section 6004 of the Affordable Care Act. This guidance fulfills the Drug Sample Transparency Act specification of ACA Section 6004. These amounts must be reported each year by April 1st for the previous calendar year.

read more
MoCRA: The Future of Cosmetic Regulations
MoCRA: The Future of Cosmetic Regulations

The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) was signed into law on December 29, 2022. This law, which provides a major overhaul of existing cosmetic regulations, requires the Food and Drug Administration (FDA) to create Good Manufacturing Practices for all cosmetics manufacturers. The law states that these established practices must include mandatory reporting of serious adverse health events caused by cosmetic products and mandatory testing of asbestos levels. This law will also include updates to cosmetic listing requirements.

read more